Last 12 months
Inside the activity.
4 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 1 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 2 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2018 Filed Mar 2, 2018 21:06 UTC |
Cheung SylviaChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 7,788 | $0.00 Strike: $50.13 | $0.00 |
DisclosureSEC source: 0001171843-18-001658 · formfour.xml · derivative · entry 1 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,788 Underlying: Common Stock · 7,788 shares Expires 2027-01-27 F1 · derivative.exercise_price: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, January 27, 2017, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 2 and 3. F2 · date: On March 2, 2018, the Compensation Committee determined and certified that 55% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 1 and 3. F3 · derivative.exercise_date: The stock options vest in three equal installments on the following dates: March 2, 2018, January 1, 2019, and January 1, 2020. Read SEC document |
| March 02, 2018 Filed Mar 2, 2018 21:06 UTC |
SHERWOOD CHARLES HDirector · CEO and Director
|
GrantStock Option (Right to Buy) · Derivative | 27,984 | $0.00 Strike: $50.13 | $0.00 |
DisclosureSEC source: 0001171843-18-001655 · formfour.xml · derivative · entry 1 SHERWOOD CHARLES H · CIK 0001244298 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,984 Underlying: Common Stock · 27,984 shares Expires 2027-01-27 F1 · derivative.exercise_price: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, January 27, 2017, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 2 and 3. F2 · date: On March 2, 2018, the Compensation Committee determined and certified that 55% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 1 and 3. F3 · derivative.exercise_date: The stock options vest in three equal installments on the following dates: March 2, 2018, January 1, 2019, and January 1, 2020. Read SEC document |
| March 02, 2018 Filed Mar 2, 2018 21:06 UTC |
Hague RichardChief Commercial Officer
|
GrantStock Option (Right to Buy) · Derivative | 7,788 | $0.00 Strike: $50.13 | $0.00 |
DisclosureSEC source: 0001171843-18-001657 · formfour.xml · derivative · entry 1 Hague Richard · CIK 0001656557 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,788 Underlying: Common Stock · 7,788 shares Expires 2027-01-27 F1 · derivative.exercise_price: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, January 27, 2017, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 2 and 3. F2 · date: On March 2, 2018, the Compensation Committee determined and certified that 55% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 1 and 3. F3 · derivative.exercise_date: The stock options vest in three equal installments on the following dates: March 2, 2018, January 1, 2019, and January 1, 2020. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:12 UTC |
WHEELER STEVE EDirector
|
GrantCommon Stock | 1,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-18-000697 · form4wheeler.xml · nonDerivative · entry 3 WHEELER STEVE E · CIK 0001250755 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,594 F3 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on January 24, 2019. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:10 UTC |
Thompson Jeffery SDirector
|
GrantCommon Stock | 1,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-18-000696 · formfour.xml · nonDerivative · entry 1 Thompson Jeffery S · CIK 0001510398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,843 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on January 24, 2019. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:09 UTC |
SHERWOOD CHARLES HDirector · CEO and Director
|
GrantCommon Stock | 57,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-18-000695 · formfour.xml · nonDerivative · entry 1 SHERWOOD CHARLES H · CIK 0001244298 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,891 F1 · security: Restricted stock awards vest in four equal annual installments beginning January 24, 2019. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:09 UTC |
Larsen Glenn R.Director
|
GrantCommon Stock | 1,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-18-000694 · formfour.xml · nonDerivative · entry 1 Larsen Glenn R. · CIK 0001633737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,103 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on January 24, 2019. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:08 UTC |
LAND RAYMOND JDirector
|
GrantCommon Stock | 1,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-18-000693 · formfour.xml · nonDerivative · entry 1 LAND RAYMOND J · CIK 0001225613 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,150 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on January 24, 2019. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:07 UTC |
Finnerty ThomasChief Human Resources Officer
|
GrantStock Option (Right to Buy) · Derivative | 6,700 | $0.00 Strike: $61.47 | $0.00 |
DisclosureSEC source: 0001171843-18-000691 · formfour.xml · derivative · entry 1 Finnerty Thomas · CIK 0001720871 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,700 Underlying: Common Stock · 6,700 shares Expires 2028-01-24 F1 · derivative.exercise_date: The stock options vest in four equal annual installments beginning January 24, 2019. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:06 UTC |
Cheung SylviaChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 21,400 | $0.00 Strike: $61.47 | $0.00 |
DisclosureSEC source: 0001171843-18-000689 · formfour.xml · derivative · entry 1 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,400 Underlying: Common Stock · 21,400 shares Expires 2028-01-24 F1 · derivative.exercise_date: The stock options vest in four equal annual installments beginning January 24, 2019. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:08 UTC |
Hague RichardChief Commercial Officer
|
GrantStock Option (Right to Buy) · Derivative | 10,700 | $0.00 Strike: $61.47 | $0.00 |
DisclosureSEC source: 0001171843-18-000692 · formfour.xml · derivative · entry 1 Hague Richard · CIK 0001656557 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,700 Underlying: Common Stock · 10,700 shares Expires 2028-01-24 F1 · derivative.exercise_date: The stock options vest in four equal annual installments beginning January 24, 2019. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:06 UTC |
Darling Joseph GPresident
|
GrantStock Option (Right to Buy) · Derivative | 21,400 | $0.00 Strike: $61.47 | $0.00 |
DisclosureSEC source: 0001171843-18-000690 · formfour.xml · derivative · entry 1 Darling Joseph G · CIK 0001433556 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,400 Underlying: Common Stock · 21,400 shares Expires 2028-01-24 F1 · derivative.exercise_date: The stock options vest in four equal annual installments beginning January 24, 2019. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:06 UTC |
Bower Joseph L.Director
|
GrantCommon Stock | 1,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-18-000688 · formfour.xml · nonDerivative · entry 1 BOWER JOSEPH I · CIK 0001227947 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,162 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on January 24, 2019. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:05 UTC |
Ahn Edward S.Chief Tech & Strategy Officer
|
GrantStock Option (Right to Buy) · Derivative | 13,400 | $0.00 Strike: $61.47 | $0.00 |
DisclosureSEC source: 0001171843-18-000687 · formfour.xml · derivative · entry 1 Ahn Edward S. · CIK 0001623597 · Chief Tech & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,400 Underlying: Common Stock · 13,400 shares Expires 2028-01-24 F1 · derivative.exercise_date: The stock options vest in four equal annual installments beginning January 24, 2019. Read SEC document |
| November 30, 2017 Filed Dec 1, 2017 21:05 UTC |
Hague RichardChief Commercial Officer
|
SaleCommon Stock | 5,250 | $54.48 | $286,020.00 |
DisclosureSEC source: 0001171843-17-007396 · formfour.xml · nonDerivative · entry 1 Hague Richard · CIK 0001656557 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,650 F1 · price: On November 30, 2017, Mr. Hague sold 5,250 shares in multiple trades ranging from $54.20 to $54.98. The price reported above reflects the weighted average sale price. Mr. Hague undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| October 30, 2017 Filed Nov 1, 2017 20:11 UTC |
Finnerty ThomasChief Human Resources Officer
|
GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $54.09 | $0.00 |
DisclosureSEC source: 0001171843-17-006489 · formfour.xml · derivative · entry 2 Finnerty Thomas · CIK 0001720871 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2017-10-30 F2 · derivative.exercise_date: The stock options vest in three equal annual installments beginning October 30, 2018. Read SEC document |
| October 30, 2017 Filed Nov 1, 2017 20:11 UTC |
Finnerty ThomasChief Human Resources Officer
|
GrantCommon Stock | 6,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-17-006489 · formfour.xml · nonDerivative · entry 1 Finnerty Thomas · CIK 0001720871 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 F1 · security: The restricted stock awards vest in three equal annual installments beginning October 30, 2018. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 20:06 UTC |
SHERWOOD CHARLES HDirector · CEO and Director
|
SaleCommon Stock | 3,278 | $60.04 | $196,811.12 |
DisclosureSEC source: 0001171843-17-006332 · formfour.xml · nonDerivative · entry 1 SHERWOOD CHARLES H · CIK 0001244298 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,791 F1 · price: On October 24, 2017, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on February 21, 2017, Dr. Sherwood sold 3,278 shares in multiple trades ranging from $60.00 to $60.10. The price reported above reflects the weighted average sale price. Dr. Sherwood undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| October 23, 2017 Filed Oct 24, 2017 20:05 UTC |
SHERWOOD CHARLES HDirector · CEO and Director
|
SaleCommon Stock | 22,228 | $60.06 | $1,335,013.68 |
DisclosureSEC source: 0001171843-17-006236 · formfour.xml · nonDerivative · entry 2 SHERWOOD CHARLES H · CIK 0001244298 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,069 F2 · price: On October 23, 2017, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on February 21, 2017, Dr. Sherwood sold 22,228 shares in multiple trades ranging from $60.00 to $60.22. The price reported above reflects the weighted average sale price. Dr. Sherwood undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| October 20, 2017 Filed Oct 24, 2017 20:05 UTC |
SHERWOOD CHARLES HDirector · CEO and Director
|
SaleCommon Stock | 5,991 | $60.04 | $359,699.64 |
DisclosureSEC source: 0001171843-17-006236 · formfour.xml · nonDerivative · entry 1 SHERWOOD CHARLES H · CIK 0001244298 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,297 F1 · price: On October 20, 2017, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on February 21, 2017, Dr. Sherwood sold 5,991 shares in multiple trades ranging from $60.00 to $60.13. The price reported above reflects the weighted average sale price. Dr. Sherwood undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 20:05 UTC |
SHERWOOD CHARLES HDirector · CEO and Director
|
SaleCommon Stock | 3,293 | $60.04 | $197,711.72 |
DisclosureSEC source: 0001171843-17-006128 · formfour.xml · nonDerivative · entry 1 SHERWOOD CHARLES H · CIK 0001244298 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed F1 · price: On October 16, 2017, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on February 21, 2017, Dr. Sherwood sold 3,293 shares in multiple trades ranging from $60.00 to $60.14. The price reported above reflects the weighted average sale price. Dr. Sherwood undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| October 13, 2017 Filed Oct 16, 2017 20:05 UTC |
SHERWOOD CHARLES HDirector · CEO and Director
|
SaleCommon Stock | 5,216 | $60.11 | $313,533.76 |
DisclosureSEC source: 0001171843-17-006079 · formfour.xml · nonDerivative · entry 2 SHERWOOD CHARLES H · CIK 0001244298 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,581 F2 · price: On October 13, 2017, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on February 21, 2017, Dr. Sherwood sold 5,216 shares in multiple trades ranging from $60.00 to $60.17. The price reported above reflects the weighted average sale price. Dr. Sherwood undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| October 12, 2017 Filed Oct 16, 2017 20:05 UTC |
SHERWOOD CHARLES HDirector · CEO and Director
|
SaleCommon Stock | 1,908 | $60.00 | $114,480.00 |
DisclosureSEC source: 0001171843-17-006079 · formfour.xml · nonDerivative · entry 1 SHERWOOD CHARLES H · CIK 0001244298 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,797 F1 · price: On October 12, 2017, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on February 21, 2017, Dr. Sherwood sold 1,908 shares in a single trade at $60.00. Read SEC document |
| July 27, 2017 Filed Jul 31, 2017 20:15 UTC |
SHERWOOD CHARLES HDirector · CEO and Director
|
SaleCommon Stock | 63,799 | $50.79 | $3,240,351.21 |
DisclosureSEC source: 0001171843-17-004472 · formfour.xml · nonDerivative · entry 1 SHERWOOD CHARLES H · CIK 0001244298 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,705 F1 · price: On July 27, 2017, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on February 21, 2017, Dr. Sherwood sold 63,799 shares in multiple trades ranging from $50.00 to $52.05. The price reported above reflects the weighted average sale price. Dr. Sherwood undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| July 27, 2017 Filed Jul 31, 2017 20:10 UTC |
Darling Joseph GPresident
|
GrantStock Option (Right to Buy) · Derivative | 41,609 | $0.00 Strike: $51.70 | $0.00 |
DisclosureSEC source: 0001171843-17-004467 · formfour.xml · derivative · entry 2 Darling Joseph G · CIK 0001433556 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,609 Underlying: Common Stock · 41,609 shares Expires 2027-07-27 F2 · derivative.exercise_date: The stock options vest in three equal annual installments beginning July 27, 2018. Read SEC document |
| July 27, 2017 Filed Jul 31, 2017 20:10 UTC |
Darling Joseph GPresident
|
GrantCommon Stock | 14,506 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-17-004467 · formfour.xml · nonDerivative · entry 1 Darling Joseph G · CIK 0001433556 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,506 F1 · security: Restricted stock awards vest in three equal annual installments beginning July 27, 2018. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 22:30 UTC |
SHERWOOD CHARLES HDirector · President, CEO, Director
|
SaleCommon Stock | 8,236 | $50.06 | $412,294.16 |
DisclosureSEC source: 0001171843-17-003991 · formfour.xml · nonDerivative · entry 2 SHERWOOD CHARLES H · CIK 0001244298 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,504 F2 · price: On July 5, 2017, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on February 21, 2017, Dr. Sherwood sold 8,236 shares in multiple trades ranging from $50.00 to $50.25. The price reported above reflects the weighted average sale price. Dr. Sherwood undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 22:30 UTC |
SHERWOOD CHARLES HDirector · President, CEO, Director
|
SaleCommon Stock | 5,965 | $50.00 | $298,250.00 |
DisclosureSEC source: 0001171843-17-003991 · formfour.xml · nonDerivative · entry 1 SHERWOOD CHARLES H · CIK 0001244298 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,740 F1 · price: On July 3, 2017, pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 on February 21, 2017, Dr. Sherwood sold 5,965 shares in multiple trades ranging from $50.00 to $50.02. The price reported above reflects the weighted average sale price. Dr. Sherwood undertakes to provide the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 22, 2017 Filed May 23, 2017 20:56 UTC |
Thompson Jeffery SDirector
|
SaleCommon Stock | 9,628 | $47.37 | $456,078.36 |
DisclosureSEC source: 0001171843-17-003274 · formfour.xml · nonDerivative · entry 2 Thompson Jeffery S · CIK 0001510398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,217 F2 · price: Represents the weighted average sales price. The shares were sold on 5/22/2017 at prices ranging from $47.25 to $47.45 per share. Full information regarding the number of shares sold at each price shall be provided to the Staff, Issuer or any security holder, upon request. Read SEC document |
| May 19, 2017 Filed May 23, 2017 20:56 UTC |
Thompson Jeffery SDirector
|
SaleCommon Stock | 1,097 | $47.58 | $52,195.26 |
DisclosureSEC source: 0001171843-17-003274 · formfour.xml · nonDerivative · entry 1 Thompson Jeffery S · CIK 0001510398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,845 F1 · price: Represents the weighted average sales price. The shares were sold on 5/19/2017 at prices ranging from $47.56 to $47.61 per share. Full information regarding the number of shares sold at each price shall be provided to the Staff, Issuer or any security holder, upon request. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:07 UTC |
SHERWOOD CHARLES HDirector · President, CEO, Director
|
GrantStock Option (Right to Buy) · Derivative | 39,375 | $0.00 Strike: $38.11 | $0.00 |
DisclosureSEC source: 0001171843-17-001208 · formfour.xml · derivative · entry 1 SHERWOOD CHARLES H · CIK 0001244298 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,375 Underlying: Common Stock · 39,375 shares Expires 2026-02-04 F1 · derivative.exercise_price: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, February 4, 2016, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 2 and 3. F2 · date: On February 24, 2017, the Compensation Committee determined and certified that 125% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 1 and 3. F3 · derivative.exercise_date: The stock options vest in four equal installments on the following dates: February 24, 2017, January 1, 2018, January 1, 2019 and January 1, 2020. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:06 UTC |
Hague RichardChief Commercial Officer
|
GrantStock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $38.11 | $0.00 |
DisclosureSEC source: 0001171843-17-001207 · formfour.xml · derivative · entry 1 Hague Richard · CIK 0001656557 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2026-02-04 F1 · derivative.exercise_price: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, February 4, 2016, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 2 and 3. F2 · date: On February 24, 2017, the Compensation Committee determined and certified that 125% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 1 and 3. F3 · derivative.exercise_date: The stock options vest in four equal installments on the following dates: February 24, 2017, January 1, 2018, January 1, 2019 and January 1, 2020. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:06 UTC |
Cheung SylviaChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $38.11 | $0.00 |
DisclosureSEC source: 0001171843-17-001206 · formfour.xml · derivative · entry 1 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2026-02-03 F1 · derivative.exercise_price: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, February 4, 2016, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 2 and 3. F2 · date: On February 24, 2017, the Compensation Committee determined and certified that 125% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 1 and 3. F3 · derivative.exercise_date: The stock options vest in four equal installments on the following dates: February 24, 2017, January 1, 2018, January 1, 2019 and January 1, 2020. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:05 UTC |
Ahn Edward S.Chief Tech & Strategy Officer
|
GrantStock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $38.11 | $0.00 |
DisclosureSEC source: 0001171843-17-001205 · formfour.xml · derivative · entry 2 Ahn Edward S. · CIK 0001623597 · Chief Tech & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2026-02-04 F1 · derivative.exercise_price: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, February 4, 2016, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 2 and 3. F2 · date: On February 24, 2017, the Compensation Committee determined and certified that 125% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 1 and 3. F3 · derivative.exercise_date: The stock options vest in four equal installments on the following dates: February 24, 2017, January 1, 2018, January 1, 2019 and January 1, 2020. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:05 UTC |
Ahn Edward S.Chief Tech & Strategy Officer
|
SaleCommon Stock | 640 | $49.47 | $31,660.80 |
DisclosureSEC source: 0001171843-17-001205 · formfour.xml · nonDerivative · entry 1 Ahn Edward S. · CIK 0001623597 · Chief Tech & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,260 Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC |
LAND RAYMOND JDirector
|
SaleCommon Stock | 2,635 | $49.08 | $129,325.80 |
DisclosureSEC source: 0001171843-17-001109 · f4_land022417.xml · nonDerivative · entry 1 LAND RAYMOND J · CIK 0001225613 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,524 Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC |
Cheung SylviaChief Financial Officer
|
Exercise / conversionStock Option (Right to buy) · Derivative | 807 | $0.00 Strike: $6.99 | $0.00 |
DisclosureSEC source: 0001171843-17-001108 · f4_cheung022417.xml · derivative · entry 9 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 807 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Exercise of 807 stock options granted on June 7, 2011 that were fully vested. F4 · derivative.expiration_date: Exercise of 807 stock options granted on June 7, 2011 that were fully vested. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC |
Cheung SylviaChief Financial Officer
|
Exercise / conversionStock Option (Right to buy) · Derivative | 4,193 | $0.00 Strike: $6.99 | $0.00 |
DisclosureSEC source: 0001171843-17-001108 · f4_cheung022417.xml · derivative · entry 8 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 4,193 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercise of 4,193 stock options granted on June 7, 2011 that are fully vested. F3 · derivative.expiration_date: Exercise of 4,193 stock options granted on June 7, 2011 that are fully vested. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC |
Cheung SylviaChief Financial Officer
|
Exercise / conversionStock Appreciation Rights · Derivative | 5,000 | $0.00 Strike: $10.99 | $0.00 |
DisclosureSEC source: 0001171843-17-001108 · f4_cheung022417.xml · derivative · entry 7 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Exercise of stock appreciation rights ("SARS") granted on January 31, 2008, which vested in full on such date, and expiring on January 31, 2018. F1 · derivative.expiration_date: Exercise of stock appreciation rights ("SARS") granted on January 31, 2008, which vested in full on such date, and expiring on January 31, 2018. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC |
Cheung SylviaChief Financial Officer
|
SaleCommon Stock | 807 | $49.02 | $39,559.14 |
DisclosureSEC source: 0001171843-17-001108 · f4_cheung022417.xml · nonDerivative · entry 6 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,608 Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC |
Cheung SylviaChief Financial Officer
|
SaleCommon Stock | 1,193 | $49.05 | $58,516.65 |
DisclosureSEC source: 0001171843-17-001108 · f4_cheung022417.xml · nonDerivative · entry 5 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,415 Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC |
Cheung SylviaChief Financial Officer
|
Exercise / conversionCommon Stock | 5,000 | $6.99 | $34,950.00 |
DisclosureSEC source: 0001171843-17-001108 · f4_cheung022417.xml · nonDerivative · entry 4 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Exercise of 4,193 stock options granted on June 7, 2011 that are fully vested. F4 · security: Exercise of 807 stock options granted on June 7, 2011 that were fully vested. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC |
Cheung SylviaChief Financial Officer
|
SaleCommon Stock | 2,000 | $49.01 | $98,020.00 |
DisclosureSEC source: 0001171843-17-001108 · f4_cheung022417.xml · nonDerivative · entry 3 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,608 Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC |
Cheung SylviaChief Financial Officer
|
Tax withholdingCommon Stock | 1,117 | $49.20 | $54,956.40 |
DisclosureSEC source: 0001171843-17-001108 · f4_cheung022417.xml · nonDerivative · entry 2 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,608 F2 · security: Reflects 1,117 shares of common stock utilized to cover the exercise price of the above listed SARs award by the Reporting Person on February 22, 2017. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC |
Cheung SylviaChief Financial Officer
|
Exercise / conversionCommon Stock | 5,000 | $10.99 | $54,950.00 |
DisclosureSEC source: 0001171843-17-001108 · f4_cheung022417.xml · nonDerivative · entry 1 Cheung Sylvia · CIK 0001572857 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Exercise of stock appreciation rights ("SARS") granted on January 31, 2008, which vested in full on such date, and expiring on January 31, 2018. Read SEC document |
| February 16, 2017 Filed Jan 26, 2018 21:12 UTC |
WHEELER STEVE EDirector
|
OtherCommon Stock | 1,158 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-18-000697 · form4wheeler.xml · nonDerivative · entry 2 WHEELER STEVE E · CIK 0001250755 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,968 F2 · security: These shares were transferred on February 16, 2017 pursuant to a settlement agreement effective June 12, 2014. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 21:14 UTC |
WHEELER STEVE EDirector
|
GrantCommon Stock | 1,994 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-17-000592 · formfour.xml · nonDerivative · entry 1 WHEELER STEVE E · CIK 0001250755 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,081 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on January 27, 2018. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 21:10 UTC |
Thompson Jeffery SDirector
|
GrantCommon Stock | 1,994 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-17-000591 · formfour.xml · nonDerivative · entry 1 Thompson Jeffery S · CIK 0001510398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,942 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on January 27, 2018. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 21:10 UTC |
SHERWOOD CHARLES HDirector · President, CEO, Director
|
GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $50.13 | $0.00 |
DisclosureSEC source: 0001171843-17-000590 · formfour.xml · derivative · entry 1 SHERWOOD CHARLES H · CIK 0001244298 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2027-01-27 F1 · derivative.exercise_date: The stock options vest in three equal annual installments beginning January 27, 2018. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 21:09 UTC |
Larsen Glenn R.Director
|
GrantCommon Stock | 1,994 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-17-000589 · formfour.xml · nonDerivative · entry 1 Larsen Glenn R. · CIK 0001633737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,477 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on January 27, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.